Τhe DCU aims to support effective and safe radionuclide therapy for cancer patients.

Partners

Radboudumc logo Erasmus MC logo TU Delft logo UMCG logo Netherlands Cancer Institute logo

2025

  1. Chatzipapas, K. P., Papachristou, K., Visvikis, D., Incerti, S., Hazle, J. D., & Kagadis, G. C. (2025). In silico assessment of cellular damage from Lu-177, Ac-225, and Pb-212 therapeutic radionuclides. Medical Physics, 52(11), e70089. https://doi.org/https://doi.org/10.1002/mp.70089
  2. Wenker, S. T. M., van Lith, S. A. M., Tamborino, G., Konijnenberg, M. W., Bussink, J., & Heskamp, S. (2025). The potential of targeted radionuclide therapy to treat hypoxic tumor cells. Nuclear Medicine and Biology, 140–141, 108971. https://doi.org/10.1016/j.nucmedbio.2024.108971

2024

  1. Chatzipapas, K. P., Tran, H. N., Dordevic, M., Sakata, D., Incerti, S., Visvikis, D., & Bert, J. (2024). Development of a novel computational technique to create DNA and cell geometrical models for Geant4-DNA. Physica Medica, 127, 104839. https://doi.org/https://doi.org/10.1016/j.ejmp.2024.104839
  2. Kleinendorst, S. C., Oosterwijk, E., Molkenboer-Kuenen, J., Frielink, C., Franssen, G. M., Boreel, D. F., Tamborino, G., Gloudemans, M., Hendrikx, M., Kroon, D., Hillen, J., Bussink, J., Muselaers, S., Mulders, P., Konijnenberg, M. W., Wheatcroft, M. P., Twumasi-Boateng, K., & Heskamp, S. (2024). Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma. Theranostics, 14(9), 3693–3707. https://doi.org/10.7150/thno.96944

2023

  1. Privé, B. M., Boussihmad, M. A., Timmermans, B., van Gemert, W. A., Peters, S. M. B., Derks, Y. H. W., van Lith, S. A. M., Mehra, N., Nagarajah, J., Heskamp, S., & Westdorp, H. (2023). Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 1906–1918. https://doi.org/10.1007/s00259-023-06144-0
  2. Mínguez Gabiña, P., Sjögreen Gleisner, K., Cremonesi, M., Stokke, C., Flux, G., Cicone, F., Konijnenberg, M., Aldridge, M., Sandstrom, M., Chiesa, C., Paphiti, M., Hippeläinen, E., Uribe, C., Solny, P., Gnesin, S., Bernhardt, P., Chouin, N., Costa, P. F., Glatting, G., … Gear, J. (2023). Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 50(9), 2595–2604. https://doi.org/10.1007/s00259-023-06215-2

2022

  1. Sjögreen Gleisner, K., Chouin, N., Minguez Gabina, P., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., Eberlein, U., & Gear, J. (2022). EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 49(6), 1778–1809. https://doi.org/10.1007/s00259-022-05727-7
  2. Weber, M., Lam, M., Chiesa, C., Konijnenberg, M., Cremonesi, M., Flamen, P., Gnesin, S., Bodei, L., Kracmerova, T., Luster, M., Garin, E., & Herrmann, K. (2022). EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging, 49(5), 1682–1699. https://doi.org/10.1007/s00259-021-05600-z
  3. Privé, B. M., Derks, Y. H. W., Rosar, F., Franssen, G. M., Peters, S. M. B., Khreish, F., Bartholomä, M., Maus, S., Gotthardt, M., Laverman, P., Konijnenberg, M. W., Ezziddin, S., Nagarajah, J., & Heskamp, S. (2022). 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. European Journal of Nuclear Medicine and Molecular Imaging, 49(6), 2064–2076. https://doi.org/10.1007/s00259-021-05661-0
  4. Kampen, W. U., Boddenberg-Pätzold, B., Fischer, M., Gabriel, M., Klett, R., Konijnenberg, M., Kresnik, E., Lellouche, H., Paycha, F., Terslev, L., Turkmen, C., van der Zant, F., Antunovic, L., Panagiotidis, E., Gnanasegaran, G., Kuwert, T., & Van den Wyngaert, T. (2022). The EANM guideline for radiosynoviorthesis. European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 681–708. https://doi.org/10.1007/s00259-021-05541-7

2021

  1. Konijnenberg, M., Herrmann, K., Kobe, C., Verburg, F., Hindorf, C., Hustinx, R., & Lassmann, M. (2021). EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 48(1), 67–72. https://doi.org/10.1007/s00259-020-05038-9
  2. Chiesa, C., Sjogreen-Gleisner, K., Walrand, S., Strigari, L., Flux, G., Gear, J., Stokke, C., Minguez Gabina, P., Bernhardt, P., & Konijnenberg, M. (2021). EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Physics, 8(1), 77. https://doi.org/10.1186/s40658-021-00394-3
  3. Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., Nagarajah, J., & Konijnenberg, M. W. (2021). Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 460–469. https://doi.org/10.1007/s00259-021-05471-4
  4. Privé, B. M., Peters, S. M. B., Muselaers, C. H. J., van Oort, I. M., Janssen, M. J. R., Sedelaar, J. P. M., Konijnenberg, M. W., Zámecnik, P., Uijen, M. J. M., Schilham, M. G. M., Eek, A., Scheenen, T. W. J., Verzijlbergen, J. F., Gerritsen, W. R., Mehra, N., & Smeenk, R. J. (2021). Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clinical Cancer Research, 27(13), 3595–3601. https://doi.org/10.1158/1078-0432.CCR-20-4298
  5. Lassmann, M., Eberlein, U., Gear, J., Konijnenberg, M., & Kunikowska, J. (2021). Dosimetry for Radiopharmaceutical Therapy: The European Perspective. Journal of Nuclear Medicine, 62(Suppl 3), 73S–79S. https://doi.org/10.2967/jnumed.121.262754

2017

  1. Sjögreen Gleisner, K., Spezi, E., Solny, P., Minguez Gabina, P., Cicone, F., Stokke, C., Chiesa, C., Paphiti, M., Brans, B., Sandström, M., Tipping, J., Konijnenberg, M., & Flux, G. (2017). Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics, 4(1), 28. https://doi.org/10.1186/s40658-017-0193-4
  2. van der Kroon, I., Woliner-van der Weg, W., Brom, M., Joosten, L., Frielink, C., Konijnenberg, M. W., Visser, E. P., & Gotthardt, M. (2017). Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin. Scientific Reports, 7, 39800. https://doi.org/10.1038/srep39800
  3. Huizing, F. J., Hoeben, B. A. W., Franssen, G., Lok, J., Heskamp, S., Oosterwijk, E., Boerman, O. C., & Bussink, J. (2017). Preclinical validation of 111In-girentuximab-F(ab’)2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts. Radiotherapy and Oncology, 124(3), 521–525. https://doi.org/10.1016/j.radonc.2017.07.025

2016

  1. Bergsma, H., Konijnenberg, M. W., van der Zwan, W. A., Kam, B. L. R., Teunissen, J. J. M., Kooij, P. P., Mauff, K. A. L., Krenning, E. P., & Kwekkeboom, D. J. (2016). Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 43(10), 1802–1811. https://doi.org/10.1007/s00259-016-3382-9
  2. Maina, T., Konijnenberg, M. W., KolencPeitl, P., Garnuszek, P., Nock, B. A., Kaloudi, A., Kroselj, M., Zaletel, K., Maecke, H., Mansi, R., Erba, P., von Guggenberg, E., Hubalewska-Dydejczyk, A., Mikolajczak, R., & Decristoforo, C. (2016). Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients. European Journal of Pharmaceutical Sciences, 91, 236–242. https://doi.org/10.1016/j.ejps.2016.05.011

2007

  1. Müller, C., Forrer, F., Bernard, B. F., Melis, M., Konijnenberg, M., Krenning, E. P., & de Jong, M. (2007). Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biotherapy and Radiopharmaceuticals, 22(1), 151–159. https://doi.org/10.1089/cbr.2007.309